EB-103 is under clinical development by Estrella Immunopharma and currently in Phase II for Mantle Cell Lymphoma. According to GlobalData, Phase II drugs for Mantle Cell Lymphoma have a 31% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how EB-103’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
EB-103 overview
EB-103 is under development for the treatment of diffuse large B-cell lymphoma (DLBCL), relapsed or refractory (R/R) B-cell non-Hodgkin lymphoma (NHL) patients, including those with human immunodeficiency virus (HIV)-associated lymphoma, follicular lymphoma and primary and secondary central nervous system (CNS) lymphoma, Burkitt lymphoma, precursor B-cell lymphoblastic lymphoma, or mantle cell lymphoma. It is an autologous T-cell therapy whereby a subject's own T cells are transduced with a lentiviral vector expressing the EB103 transgene. The therapeutic candidate acts by targeting cells expressing CD19 and is being developed based on ARTEMIS (Antibody Redirected T Cells with Endogenous Modular Immune Signaling) cell receptor platform. It is administered through parenteral route.
Estrella Immunopharma overview
Estrella Immunopharma, a subsidiary of Estrella Immunopharma, is a biopharmaceutical company that develops T-cell therapies for the treatment of blood cancers and solid tumors treatments. The company is headquartered in Emeryville, California, the US.
For a complete picture of EB-103’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
